Abstract Search

ea0099p423 | Adrenal and Cardiovascular Endocrinology | ECE2024

Baseline characteristics of adults with classic congenital adrenal hyperplasia enrolled in CAHtalyst, a phase 3 study of Crinecerfont, a corticotropin-releasing factor type 1 receptor antagonist

Auchus Richard , Hamidi Oksana , Pivonello Rosario , Bancos Irina , Witchel Selma , Isidori Andrea , Rodien Patrice , Srirangalingam Umasuthan , Kiefer Florian , Falhammar Henrik , Merke Deborah , Reisch Nicole , Sturgeon Julia , Roberts Eiry , Lin Vivian , Chan Jean L , Farber Robert

Objectives: To describe the baseline characteristics of individuals enrolled in CAHtalyst (NCT04490915), a randomized, double-blind, placebo-controlled, Phase 3 study evaluating the safety and efficacy of crinecerfont (a corticotropin-releasing factor type 1 receptor [CRF1] antagonist) in adults with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21-OHD).Methods: The study included adults (age ≥18 years) with cl...

4 shares

Endocrine Abstracts

Baseline characteristics of adults with classic congenital adrenal hyperplasia enrolled in CAHtalyst, a phase 3 study of Crinecerfont, a corticotropin-releasing factor type 1 receptor antagonist

BiosciAbstracts